EMEA-002465-PIP01-18

Key facts

Active substance
Fibroblast activation protein alpha-targeted interleukin 2 variant immunocytokine
Therapeutic area
Oncology
Decision number
P/0032/2019
PIP number
EMEA-002465-PIP01-18
Pharmaceutical form(s)
Solution for infusion
Condition(s) / indication(s)
Treatment of non-small cell lung cancer
Route(s) of administration
Intravenous use
Contact for public enquiries
Roche Registration GmbH

Tel. +41 6168 79411
E-mail: global.paediatrics@roche.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating